Rob Weyant, Centers for Disease Control and Prevention—Synthetic DNA and the Select Agent Regulations.

Claudia Mickelson, Massachusetts Institute of Technology—IBC, RAC guidelines and concerns about sequences.

Edward You, Federal Bureau of Investigation—Surveillance of Select Agent list and emerging concerns.

Amy Patterson, National Institutes of Health, Office of Biotechnology Activities—Comprehensive view and the need for this study.

Panel discussion: ~30 min

10:30 a.m.

Break

10:45 a.m.

Session 2: Current Mechanisms and Criteria for Screening and Surveillance

What is currently being done? How are sequences chosen to monitor? What is a “sequence of concern”?

*Moderator—John Mulligan

Pete Pesenti, Department of Homeland Security—What are the factors and process used for risk assessment? What are the criteria or characteristics of agents (or sequences) considered a threat?

John Mulligan, Blue Heron Biotechnology—What are the current screening practices, standards, and procedures in the industry? What are challenges and concerns?

Marcus Graf, GeneArt and Claes Gustafsson, DNA 2.0—Representing companies working to harmonize screening techniques. What would they like to know to help the decision making process?

Stephen M. Maurer, University of California at Berkeley—Interface of biosecurity, synthetic biology, and industry.

Panel discussion: ~30 min ** Ed You, FBI will join panel **



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement